0001209191-21-023140.txt : 20210325 0001209191-21-023140.hdr.sgml : 20210325 20210325213959 ACCESSION NUMBER: 0001209191-21-023140 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210325 FILED AS OF DATE: 20210325 DATE AS OF CHANGE: 20210325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROOT JONATHAN D CENTRAL INDEX KEY: 0001225480 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 21774401 MAIL ADDRESS: STREET 1: 2735 SAND HILL ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-739-6451 MAIL ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-03-25 0 0001710072 Edgewise Therapeutics, Inc. EWTX 0001225480 ROOT JONATHAN D C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE. BOULDER CO 80303 1 0 0 0 Series B-1 Preferred Stock 0.00 Common Stock 1651607 I See Footnotes Series B-2 Preferred Stock 0.00 Common Stock 1366707 I See Footnotes Series C Preferred Stock 0.00 Common Stock 455229 I See Footnotes Immediately prior to the completion of the Issuer's initial public offering of Common Stock, each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock shall be exchanged at a 1:1 ratio for shares of Common Stock. These securities are held of record by U.S. Venture Partners XI,L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting an dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Exhibit 24 - Power of Attorney /s/ John R. Moore Attorney-in-Fact for Jonathan Root, M.D. 2021-03-25 EX-24.3_975597 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Edgewise Therapeutics, Inc. (the Company), hereby constitutes and appoints Kevin Koch, Ph.D., R. Michael Carruthers and John R. Moore, and each of them, as the true and lawful attorney-in-fact of the undersigned to: 1. prepare, execute in the name of the undersigned and on the behalf of the undersigned, and submit the Securities and Exchange Commission (the SEC) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC or reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and 2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of the undersigned of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of March, 2021. Signature: /s/Jonathan Root, M.D. Print Name: /s/Jonathan Root, M.D.